S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
Log in

NASDAQ:BNTC - BENITEC BIOPHAR/S Stock Price, Forecast & News

$5.05
-0.07 (-1.37 %)
(As of 01/20/2020 04:00 PM ET)
Today's Range
$4.86
Now: $5.05
$5.42
50-Day Range
$4.23
MA: $4.89
$5.56
52-Week Range
$4.13
Now: $5.05
$24.00
Volume72,186 shs
Average Volume25,324 shs
Market Capitalization$6.46 million
P/E RatioN/A
Dividend YieldN/A
Beta1.85
Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. It also offers BB-401 and BB-501 for the treatment of oncology related to head and neck squamous cell carcinoma. The company was founded in 1995 and is headquartered in North Sydney, Australia.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BNTC
CUSIPN/A
CIKN/A
Phone61-3-8692-7222

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.52 million
Cash Flow$2.40 per share
Book Value$13.17 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$6.46 million
Next Earnings DateN/A
OptionableNot Optionable

Receive BNTC News and Ratings via Email

Sign-up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.


BENITEC BIOPHAR/S (NASDAQ:BNTC) Frequently Asked Questions

What is BENITEC BIOPHAR/S's stock symbol?

BENITEC BIOPHAR/S trades on the NASDAQ under the ticker symbol "BNTC."

Has BENITEC BIOPHAR/S been receiving favorable news coverage?

News stories about BNTC stock have been trending somewhat positive this week, according to InfoTrie. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BENITEC BIOPHAR/S earned a news impact score of 1.7 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for BENITEC BIOPHAR/S.

Who are some of BENITEC BIOPHAR/S's key competitors?

What other stocks do shareholders of BENITEC BIOPHAR/S own?

Who are BENITEC BIOPHAR/S's key executives?

BENITEC BIOPHAR/S's management team includes the folowing people:
  • Dr. Jerel A. Banks, CEO & Exec. Chairman
  • Ms. Georgina Kilfoil, Chief Devel. Officer (Age 50)
  • Ms. Megan Joan Boston, Exec. Director & Head of Operations - Australia
  • Mr. Bryan Dulhunty, Chief Financial Officer
  • Dr. Michael Graham, Head of Discovery & Founding Scientist

When did BENITEC BIOPHAR/S IPO?

(BNTC) raised $0 in an initial public offering (IPO) on Thursday, August 6th 2015. The company issued 0 shares at $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

How do I buy shares of BENITEC BIOPHAR/S?

Shares of BNTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BENITEC BIOPHAR/S's stock price today?

One share of BNTC stock can currently be purchased for approximately $5.05.

How big of a company is BENITEC BIOPHAR/S?

BENITEC BIOPHAR/S has a market capitalization of $6.46 million and generates $12.52 million in revenue each year. View Additional Information About BENITEC BIOPHAR/S.

What is BENITEC BIOPHAR/S's official website?

The official website for BENITEC BIOPHAR/S is http://www.benitec.com/.

How can I contact BENITEC BIOPHAR/S?

BENITEC BIOPHAR/S's mailing address is Level 14 114 William St, Melbourne C3, 3000. The biotechnology company can be reached via phone at 61-3-8692-7222 or via email at [email protected]


MarketBeat Community Rating for BENITEC BIOPHAR/S (NASDAQ BNTC)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  168 (Vote Outperform)
Underperform Votes:  193 (Vote Underperform)
Total Votes:  361
MarketBeat's community ratings are surveys of what our community members think about BENITEC BIOPHAR/S and other stocks. Vote "Outperform" if you believe BNTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BNTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel